BNP Paribas Financial Markets Invests $42,000 in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

BNP Paribas Financial Markets bought a new stake in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 2,728 shares of the company’s stock, valued at approximately $42,000.

Separately, Charles Schwab Investment Management Inc. bought a new stake in Artiva Biotherapeutics during the 3rd quarter valued at about $623,000.

Artiva Biotherapeutics Trading Up 0.3 %

Shares of Artiva Biotherapeutics stock opened at $10.00 on Friday. The business’s 50-day simple moving average is $11.72. Artiva Biotherapeutics, Inc. has a 1 year low of $9.68 and a 1 year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). As a group, equities research analysts forecast that Artiva Biotherapeutics, Inc. will post -4.68 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on ARTV shares. Wedbush restated an “outperform” rating and issued a $18.00 target price on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Needham & Company LLC reissued a “buy” rating and issued a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, Artiva Biotherapeutics presently has a consensus rating of “Buy” and an average price target of $21.25.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.